Overview

Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

Status:
COMPLETED
Trial end date:
2025-06-27
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction from baseline in liver fat content (LFC) after 28 weeks, as well as the safety and tolerability of the different regimens of efinopegdutide.
Phase:
PHASE2
Details
Lead Sponsor:
Merck Sharp & Dohme LLC